Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

Central Nervous System Disorders (CNSD) Following Hematopoietic Stem Cell Transplantation (HSCT): A Prospective Study from the Infectious Diseases Working Party (IDWP) and the Transplant Complications Working Party (TCWP), European Society of Blood and Marrow Transplantation (EBMT)

Blood (2024) 144 (Supplement 1): 3497.

https://doi.org/10.1182/blood-2024-194695

Published: 2024

Journal Articles

Similar Transplant Outcomes for Haplo and MUD Allo-Hcts in AML Patients Achieving CR2: A Study Analyzing 4030 Allo-HCT Recipients from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Blood (2024) 144 (Supplement 1): 3562.

https://doi.org/10.1182/blood-2024-200458

Published: 2024

Journal Articles

Optimizing Haploidentical Transplant for Adults with Acute Lymphoblastic Leukemia: The Role of Donor and Graft Selection. a Study from the ALWP of the EBMT

Blood (2024) 144 (Supplement 1): 2193.

https://doi.org/10.1182/blood-2024-208242

Published: 2024

Journal Articles

Post-Transplant Cyclophosphamide Versus Antithymocyte Globulin in Haploidentical Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT

Blood (2024) 144 (Supplement 1): 4944.

https://doi.org/10.1182/blood-2024-207391

Published: 2024

Journal Articles

Score to Guide Donor Choice in Haploidentical Stem Cell Transplant Using Post-Transplant Cyclophosphamide for Patients with Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT

Blood (2023) 142 (Supplement 1): 4932.

https://doi.org/10.1182/blood-2023-180075

Published: 2023

Journal Articles

Non-T-Depleted Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Patients with Relapsed/Refractory Secondary Versus De Novo AML: A Study from the ALWP/EBMT

Arnon Nagler, Myriam Labopin, Johanna Tischer, Anna Maria Raiola, Desiree Kunadt, Jan Vydra, Didier Blaise, Simona Sica, Renato Fanin, Julia Winkler, Edouard Forcade, Gwendolyn Van Gorkom, Fabio Ciceri, Mohamad Mohty

Blood (2023) 142 (Supplement 1): 1049.

https://doi.org/10.1182/blood-2023-173636

Published: 2023

Journal Articles

Graft-Versus-Leukemia Effect Is Independent from Graft-Versus-Host Disease Following Ptcy-Based HLA-Haploidentical Transplantation

Frederic Baron, Myriam Labopin, Johanna Tischer, Anna Maria Raiola, Jan Vydra, Didier Blaise, Patrizia Chiusolo, Friedrich Stölzel, Renato Fanin, Patrice Chevallier, Arnon Nagler, Fabio Ciceri, Mohamad Mohty

Blood (2022) 140 (Supplement 1): 7752–7753.

https://doi.org/10.1182/blood-2022-166023

Published: 2022

Journal Articles

Impact of Fourth Methotrexate Dose in ATG-Cyclosporine GvHD Prophylaxis in HLA-Matched Unrelated HSCT: A GITMO Study

Blood (2022) 140 (Supplement 1): 10514–10516.

https://doi.org/10.1182/blood-2022-162853

Published: 2022

Journal Articles

Hematologic Recovery after Allogeneic Transplantation: Risk Factors and Its IMPACT on Transplant Related Mortality

Sabrina Giammarco, Carmen Di Grazia, Anna Maria Raiola, Stefania Bregante, Riccardo Varaldo, Francesca Gualandi, Simona Sica, Patrizia Chiusolo, Federica Sora, Luca Laurenti, Elisabetta Metafuni, Andrea Bacigalupo, Emanuele Angelucci

Blood (2021) 138 (Supplement 1): 2867.

https://doi.org/10.1182/blood-2021-147903

Published: 2021

Journal Articles

Post-Transplant Cyclophosphamide in Acute Leukemia Patients Receiving More Than 5/10 HLA-Mismatched Allogeneic Stem Cell Transplantation: A Study on Behalf of the ALWP of the EBMT

Blood (2021) 138 (Supplement 1): 3890.

https://doi.org/10.1182/blood-2021-151087

Published: 2021

Journal Articles

Total Marrow Irradiation for Second Allogeneic Haematopoietic Stem Cell Transplantation in Patients with Advanced Acute Leukemia

Alida Dominietto, MD, Stefano Vagge, MD, Susanta Hui, PhD, Carmen Di Grazia, MD, Teresa Lamparelli, MD, Stefania Bregante, MD, Anna Maria Raiola, MD, Riccardo Varaldo, MD, Francesca Gualandi, MD, Renzo Corvò, MD, Emanuele Angelucci, MD

Blood (2020) 136 (Supplement 1): 32.

https://doi.org/10.1182/blood-2020-140669

Published: 2020

Journal Articles

Outcome of 673 Patients with Hematologic Malignancies Surviving at Least 8 YEARS Post- Allogeneic Transplants: Risk Factors and Quality of Life

Giuseppe Sapienza, MD, Teresa Lamparelli, Alida Dominietto, MD, Anna Maria Raiola, MD, Carmen Di Grazia, MD, Francesca Gualandi, Simona Sica, MD, Elisabetta Metafuni, Emanuele Angelucci, MD, Andrea Bacigalupo, MD

Blood (2019) 134 (Supplement_1): 4601.

https://doi.org/10.1182/blood-2019-131959

Published: 2019

Journal Articles

Full Donor Chimerism after Allografts for Myelofibrosis: The Role of Conditioning Regimen

Patrizia Chiusolo, Sabrina Giammarco, MD PhD, Teresa Lamparelli, Lucia Casarino, Monica Rossi, Alida Dominietto, MD, Anna Maria Raiola, MD, Francesca Gualandi, Carmen Di Grazia, MD, Silvia Betti, MD PhD, Federica Sorà, MD, Elena Rossi, MD PhD, Luciana Teofili, MD, Simona Sica, MD, Andrea Bacigalupo, MD, Emanuele Angelucci, MD

Blood (2019) 134 (Supplement_1): 4490.

https://doi.org/10.1182/blood-2019-126711

Published: 2019

Journal Articles

The Impact of Aminoacid Substitution at Position 116 Class I HLA, in Unrelated Donor Transplants

Patrizia Chiusolo, Teresa Lamparelli, Giuseppe Sapienza, MD, Alida Dominietto, MD, Anna Maria Raiola, MD, Carmen Di Grazia, MD, Sabrina Giammarco, MD PhD, Francesca Gualandi, Elisabetta Metafuni, Monica Rossi, Gessica Minnella, Simona Sica, MD, Andrea Bacigalupo, MD, Emanuele Angelucci, MD

Blood (2019) 134 (Supplement_1): 4620.

https://doi.org/10.1182/blood-2019-130614

Published: 2019

Journal Articles

Unmanipulated Haploidentical Marrow Transplantation with a Modified Post-Transplant Cyclophosphamide (PT-CY) Regimen: An Update on 444 Patients

Andrea Bacigalupo, MD, Anna Maria Raiola, MD, Alida Dominietto, MD, Carmen Di Grazia, MD, Stefania Bregante, Francesca Gualandi, Maria Teresa Van Lint, MD, Patrizia Chiusolo, MD, Luca Laurenti, MD, Federica Sora, Sabrina Giammarco, MD PhD, Simona Sica, MD, Emanuele Angelucci, MD

Blood (2018) 132 (Supplement 1): 3351.

https://doi.org/10.1182/blood-2018-99-118850

Published: 2018

Journal Articles

Pre-Transplant Minimal Residual Disease Evaluation Performed By Molecular WT1-Based or Multicolor Flow Cytometry Assessment Overcomes the Prognostic Value of Cytogenetic and Molecular Risk Factors at Diagnosis in Advanced Acute Myeloid Leukemia Patients

Fabio Guolo, MD, Paola Minetto, MD, Marino Clavio, MD, Nicoletta Colombo, PhD, Annalisa Kunkl, MD, Enrico Carminati, Carmen Di Grazia, MD, Anna Maria Raiola, MD, Filippo Ballerini, MD, Maurizio Miglino, PhD, Emanuele Angelucci, Roberto M Lemoli, MD, Marco Gobbi, MD

Blood (2017) 130 (Supplement 1): 3316.

https://doi.org/10.1182/blood.V130.Suppl_1.3316.3316

Published: 2017

Journal Articles

The Effect of Prolonged Graft Versus Myelofibrosis May Influence the Prognosis of Patients with Myelofibrosis Relapsing after Allogenic Hematopoietic Stem Cell Transplantation: A Single Center Experience

Daniele Avenoso, Stefania Bregante, Anna Maria Raiola, MD, Riccardo Varaldo, Francesca Gualandi, Alida Dominietto, MD, Giannoni Livia, Carlo Marani, Carmen Di Grazia, MD, Teresa Lamparelli, Maria Teresa van Lint, Emanuele Angelucci

Blood (2017) 130 (Supplement 1): 5539.

https://doi.org/10.1182/blood.V130.Suppl_1.5539.5539

Published: 2017

Journal Articles

Early Minimal Residual Disease Assessment after Acute Myeloid Leukemia Induction with Fludarabine Cytarabine and Idarubicin (FLAI) Provides the Most Useful Prognostic Information

Paola Minetto, MD, Fabio Guolo, MD, Marino Clavio, MD, Annalisa Kunkl, MD, Nicoletta Colombo, PhD, Enrico Carminati, Giuseppina Fugazza, Simona Matarese, MD, Daniela Guardo, MD, Filippo Ballerini, MD, Carmen Di Grazia, MD, Anna Maria Raiola, MD, Antonia Cagnetta, MD, Michele Cea, Maurizio Miglino, PhD, Roberto Massimo Lemoli, MD, Marco Gobbi, MD

Blood (2017) 130 (Supplement 1): 5047.

https://doi.org/10.1182/blood.V130.Suppl_1.5047.5047

Published: 2017

Journal Articles

Minimal Residual Disease Assessment May Drive Post Remission Therapy in Acute Myeloid Leukemia. It's Time for MRD-Driven Therapy

Paola Minetto, MD, Fabio Guolo, MD, Marino Clavio, MD, Annalisa Kunkl, MD, Filippo Ballerini, MD, Nicoletta Colombo, PhD, Enrico Carminati, Giuseppina Fugazza, Giordana Pastori, MD, Simona Matarrese, Carmen Di Grazia, MD, Anna Maria Raiola, MD, Andrea Bacigalupo, MD, Roberto Massimo Lemoli, MD, Maurizio Miglino, PhD, Marco Gobbi, MD

Blood (2016) 128 (22): 2895.

https://doi.org/10.1182/blood.V128.22.2895.2895

Published: 2016

Journal Articles

A Modified Post-Transplant Cyclophosphamide (PT-CY) Regimen, Following Unmanipulated Haploidentical Bone Marrow Transplantation, for Acute Myeloid Leukemia: A Multicenter Study

Patrizia Chiusolo, MD, Gesine Bug, Attilio Olivieri, MD, Brune Mats, MD, Nicola Mordini, MD, Emilio Paolo Alessandrino, MD, Alida Dominietto, MD, Anna Maria Raiola, MD, Carmen Di Grazia, MD, Francesca Gualandi, MD, Maria Teresa van Lint, MD, Emanuele Angelucci, MD, Andrea Bacigalupo, MD

Blood (2016) 128 (22): 1234.

https://doi.org/10.1182/blood.V128.22.1234.1234

Published: 2016

NARROW

Central Nervous System Disorders (CNSD) Following Hematopoietic Stem Cell Transplantation (HSCT): A Prospective Study from the Infectious Diseases Working Party (IDWP) and the Transplant Complications Working Party (TCWP), European Society of Blood and Marrow Transplantation (EBMT)

Similar Transplant Outcomes for Haplo and MUD Allo-Hcts in AML Patients Achieving CR2: A Study Analyzing 4030 Allo-HCT Recipients from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Optimizing Haploidentical Transplant for Adults with Acute Lymphoblastic Leukemia: The Role of Donor and Graft Selection. a Study from the ALWP of the EBMT

Post-Transplant Cyclophosphamide Versus Antithymocyte Globulin in Haploidentical Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT

Score to Guide Donor Choice in Haploidentical Stem Cell Transplant Using Post-Transplant Cyclophosphamide for Patients with Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT

Non-T-Depleted Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Patients with Relapsed/Refractory Secondary Versus De Novo AML: A Study from the ALWP/EBMT

Graft-Versus-Leukemia Effect Is Independent from Graft-Versus-Host Disease Following Ptcy-Based HLA-Haploidentical Transplantation

Impact of Fourth Methotrexate Dose in ATG-Cyclosporine GvHD Prophylaxis in HLA-Matched Unrelated HSCT: A GITMO Study

Hematologic Recovery after Allogeneic Transplantation: Risk Factors and Its IMPACT on Transplant Related Mortality

Post-Transplant Cyclophosphamide in Acute Leukemia Patients Receiving More Than 5/10 HLA-Mismatched Allogeneic Stem Cell Transplantation: A Study on Behalf of the ALWP of the EBMT

Total Marrow Irradiation for Second Allogeneic Haematopoietic Stem Cell Transplantation in Patients with Advanced Acute Leukemia

Outcome of 673 Patients with Hematologic Malignancies Surviving at Least 8 YEARS Post- Allogeneic Transplants: Risk Factors and Quality of Life

Full Donor Chimerism after Allografts for Myelofibrosis: The Role of Conditioning Regimen

The Impact of Aminoacid Substitution at Position 116 Class I HLA, in Unrelated Donor Transplants

Unmanipulated Haploidentical Marrow Transplantation with a Modified Post-Transplant Cyclophosphamide (PT-CY) Regimen: An Update on 444 Patients

Pre-Transplant Minimal Residual Disease Evaluation Performed By Molecular WT1-Based or Multicolor Flow Cytometry Assessment Overcomes the Prognostic Value of Cytogenetic and Molecular Risk Factors at Diagnosis in Advanced Acute Myeloid Leukemia Patients

The Effect of Prolonged Graft Versus Myelofibrosis May Influence the Prognosis of Patients with Myelofibrosis Relapsing after Allogenic Hematopoietic Stem Cell Transplantation: A Single Center Experience

Early Minimal Residual Disease Assessment after Acute Myeloid Leukemia Induction with Fludarabine Cytarabine and Idarubicin (FLAI) Provides the Most Useful Prognostic Information

Minimal Residual Disease Assessment May Drive Post Remission Therapy in Acute Myeloid Leukemia. It's Time for MRD-Driven Therapy

A Modified Post-Transplant Cyclophosphamide (PT-CY) Regimen, Following Unmanipulated Haploidentical Bone Marrow Transplantation, for Acute Myeloid Leukemia: A Multicenter Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only